×

RNS Number : 1752F

Concepta PLC

26 July 2016

 

26 July 2016

Concepta plc ("Concepta" or the "Company")

Admission to AIM

 

Concepta plc (AIM:CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, announces that Admission of its Enlarged Share Capital to trading on AIM has now commenced under the symbol "CPT". SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Capital as Broker.

 

·     Innovative player in the Mobile Health and Connected Health Sector

·     Developed pioneering product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive

·     MyLotus – only known consumer product to allow both quantitative and qualitative measurement of a woman's personal hCG and LH hormone levels in urine samples to help increase conception rates

·     Defined route to market:

o  Regulatory approvals in place for launch in China – first order from distributor with payment in advance expected after AIM admission

o  CE-Marking for UK and Europe to follow in 2017

·     Significant market opportunity – Chinese and EU infertility market worth c.£600m per annum

·     Management has proven track record in the women's health diagnostics industry

·     New Product Development growth opportunities – proprietary platform lends itself to wider family home-health monitoring to improve individual health parameters including chronic stress, inflammation, urinary tract and healthy pregnancy progression et al.

 

Concepta's AIM Admission follows a reverse takeover from Frontier Resources International plc ("Frontier"), the details of which can be found in the announcement made by Frontier on 25 July 2016 'Result Of General Meetings And Open Offer'.

 

Erik Henau, Chief Executive Officer of Concepta plc said: "We are delighted to be joining AIM at this transformational juncture of our development and believe our listing will significantly enhance our profile and visibility with future customers and partners, as we look to launch our pioneering 'My Lotus' product, targeted at helping women with unexplained infertility to conceive, across key international growth markets.

 

"Unexplained infertility refers to women who have been unable to conceive after six months of trying for a baby. The issue is universal and largely unaffected by demographics, and accounts for 0.36% of the total population in any given market.  Many women within this group often have to wait months or even years before they are eligible for medical intervention which can lead to a long and worrying wait for women and families, not knowing whether or not anything is wrong.  As such, the market opportunity for a 'best in class' product specifically aiming to help women with unexplained infertility to conceive is huge, representing a highly motivated yet neglected group. 

 

"We are expecting a highly active start to our life on AIM, with the roll out of My Lotus in China set to commence in Q3 2016 and thereafter in the UK and Europe in 2017.  In addition, our proprietary platform lends itself to wider family home-health monitoring, and we believe there are exciting growth opportunities for Concepta in the future within the growing global connected healthcare sector set to be worth $61bn by 2020 (PwC).

 

"Finally, the board joins me in welcoming our new and existing shareholders to our register and we now look forward to implementing our defined growth strategy focused on delivering commercial success and becoming the global market leaders for over-the counter products for women with fertility issues."

 

**ENDS**

 

Enquiries:

The Company

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin/Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles/ Joe Burgess/ Josh Cole

Tel: +44 (0) 7748 843 871

 

About Concepta Plc:

 

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

 

Founded in 2013, Concepta has developed a revolutionary flagship product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive.  

 

MyLotus is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.  Competitor products currently only allow qualitative measurement and are based on the 'average woman'.  

 

Concepta has a defined route to market for its new 'My Lotus' product with Regulatory approvals for launch in China in place for 2016 and CE-Marking for UK and Europe to follow in 2017 where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCPGURUMUPQGQA

Close

×

RNS Number : 0632F

Genedrive PLC

25 July 2016

 

RNS

 

For release: 25 July 2016

 

Genedrive plc ("Genedrive" or the "Company")

 

Re change of name, TIDM and website address

 

 

Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to obtaining shareholder approval on 11 July 2016, Epistem Holdings plc has been renamed Genedrive plc and the Company's TIDM will change to GDR from 08:00 today. The Company's website address has changed to www.genedriveplc.com.

 

The name change follows the Company's recent £6.5m fundraising and reflects Genedrive's focus on the development and commercialisation of its disruptive molecular diagnostic device which targets market opportunities across infectious diseases and patient genotyping.

 

David Budd, CEO of Genedrive, commented: "While the Epistem name was reflective of the heritage of the Company, the change to Genedrive clearly reflects our intention to focus our resources on the global market opportunities in near patient and point of care molecular diagnostics. We have an opportunity to play a significant role in delivering sophisticated diagnostic testing that today millions of people cannot access. We are excited by the future of Genedrive® in bringing the power of hospital-based, central laboratory diagnostics closer to the point of need and the patient setting. Our renewed focus and the recent successful fundraising put us in a strong position to deliver on our diagnostics platform's potential and expand its testing capabilities."

 

The Genedrive® device and tests are designed to bring the power of central laboratory molecular diagnostics to point of care and point of need settings. The Company's tuberculosis/rifampicin resistance (MTB/RIF) test has been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

The Company's technology platform has broad applicability and is currently also being applied to diverse targets such as biohazard identification in a $7.8m programme with the US Department of Defense, aquaculture viral identification with the UK Centre for Environment Fisheries and Aquaculture  Science, and has also recently been validated in human genotyping applications.

 

Genedrive continues to provide contract research services to drug development companies under the Epistem brand name.

 

– Ends –

 

For further details please contact:

Genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need or point of care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

Genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.co.uk

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CANDBGDRUUDBGLS

Close

×

RNS Number : 5582E

Pennant International Group PLC

19 July 2016

 

                                                                                     

19 July 2016

Pennant International Group plc (AIM: PEN)

Record Order Book Drives Expansion of Pennant's Business Premises

Pennant International Group plc, ("Pennant" or "the Group"), the AIM quoted supplier of integrated logistic support solutions, products and services, principally to the defence, rail, aerospace and naval sectors and to Government departments, is pleased to announce that in response to the need for additional design, development and production capacity resulting from a record order book and increasing business capabilities, Pennant has taken possession of two commercial premises at Staverton Connection Business Park, Cheltenham.

The new premises, which have a combined floor area of over 8, 000 sq. ft. (743 m2) will almost double Pennant's production capacity to over 20,000 sq. ft. (1,858 m2) and are located a short distance from the Group's existing facilities in Cheltenham.

Work has already commenced fitting out the interiors of the premises, which includes the installation of offices, canteen/kitchen facilities, and mezzanine floors covering 1,600 sq. ft. of workspace. It is expected that the new facilities will be fully operational by the beginning of September.

Commenting on the new facilities, Pennant's Chief Financial Officer, Phil Walker, said: "This long-term investment provides a clear indication of our confidence in the future growth, prosperity and success of the Group."

Enquiries:
Pennant International Group plc	www.pennantplc.co.uk
Phil Walker, CFO	+44 (0) 1452 714 914
Chris Snook, CEO	+44 (0) 1452 714 914
WH Ireland Limited	www.wh-ireland.co.uk
Mike Coe / Ed Allsopp	+44 (0) 117 945 3470
Walbrook PR	www.walbrookpr.com
Paul Vann / Tom Cooper	+44 (0) 117 985 8989 Mob: 07768 807631

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALIFSEDEIALIR

Close

×

RNS Number : 3785E

Nasstar PLC

18 July 2016

 

Nasstar plc

("Nasstar", "Company" or "Group")

Nasstar rebrand and website Launch

18th July 2016

 

Nasstar (stock code: NASA), a provider of hosted managed and cloud computing services, is pleased to announce the delivery of a key strategic aim for 2016 with the launch of its new website, www.nasstar.com, under a single Nasstar brand with a new look and feel, properly reflecting the size and sophistication of the Group today.

 

Whilst we have now integrated many of the teams, processes and service offerings acquired in the last three years, the Nasstar, e-know.net, Kamanchi and VESK brands have still been going to market under their respective names, causing a level of confusion amongst clients buying services across the Group.

 

The new launch will see all operating divisions consolidate under one Nasstar brand, with investment made into a single fully integrated sales and marketing plan. The aim of the brand consolidation is to maximise the respective strengths of the various offerings within the Group and to help differentiate the full stack of services that the Group can offer, thus ensuring maximum cross sell capabilities and revenue synergy opportunities. We will continue to specialise in selected vertical markets, though we plan to widen the spread, capitalising and building on collective experience and establishing knowledge and expertise in new vertical sectors.

 

The launch of the new brand and web site will see e-know.net Ltd immediately renamed as Nasstar Group Ltd and the www.e-know.net domain being retired and redirected to www.nasstar.com.  Over the coming months, as the new Nasstar brand gets established within the recruitment sector, the Kamanchi Ltd name will change to Nasstar For Recruitment Ltd and the VESK name will be dropped once Nasstar is established within the G-Cloud market place.  Thus within six months the entire group is expected to be operating under the Nasstar brand.

 

For further information, please contact:-

 

Nasstar plc                                                                   +44 (0) 1952 225 000

Nigel Redwood, Chief Executive Officer               

Niki Redwood, Finance Director                          

 

finnCap Limited (Nominated Adviser & Broker)               +44 (0) 20 7220 0500

Julian Blunt, James Thompson (Corporate Finance)

Stephen Norcross (Corporate broking)

 

 

About Nasstar plc

Nasstar (www.nasstar.com) and its wholly owned operating businesses provide hosted managed and cloud computing services that enable subscribers to access their corporate desktop, files, applications, data and email in the Cloud rather than using local server infrastructure. Nasstar specialise in building bespoke cloud hosted services to manage a client's entire application set, tailor made to suit specific industries, designing public, private and hybrid cloud solutions to meet the objectives of the client. The solution is a highly scalable service that provides benefits including anywhere access to computing, a standardised corporate solution that can be accessed globally and in multiple languages and cost savings when compared to the traditional IT ownership model, replacing capital expenditure with a simple usage based payment model.

 

Nasstar (AIM:NASA) was founded in 1998, admitted to AIM in December 2005, acquired e-know.net Limited in a reverse takeover in January 2014, Kamanchi Limited in July 2014 and VESK in October 2015.

 

Ends

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCKMGMNKKZGVZM

Close

×

RNS Number : 3920E

Crimson Tide PLC

18 July 2016

 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected by large UK retailer

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 – Smart Mobility as a Service, has won a contract with a large UK retailer whereby mpro5 will be used to monitor store safety, cleanliness and security. The initial contract value for a pilot period is approximately £200,000. Subject to a successful pilot period, the retailer will deploy mpro5 for a 48-month term with a considerably higher value.

The roll-out involves implementing the mobility platform to enable the scheduling of regular cleaning, reactive cleaning and incident capture as well as providing dynamic audits and bespoke management dashboards.  Jobs are scheduled via the mpro5 website, and are then pushed to a mobile device.  Remote users monitor business workflows and capture pertinent information which is then automatically synchronised with the cloud to the central repository.  Real time audit dashboards and reports are securely shared to relevant management.

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security.  This enables real-time information upload, quick verifications and multi-way data request transmittals.

This customer stands to benefit from improvements in reporting and visibility, quality auditing, health and safety, financial savings, consumer satisfaction and overall efficiency and productivity. mpro5 provides additional protection against any spurious 'slip-and-trip' claims in large, multi-site retail environments.

Barrie Whipp, Executive Chairman of Crimson Tide, said: "Our team has worked diligently in providing a solid business case to our client, which has resulted in this success.  I am delighted we are able to assist this household-name customer in transforming its business and ultimately providing true ROI using mpro5."

 

‐ ends ‐

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp                                                                                       01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister                                                             020 7220 1666

Allerton Communications

Peter Curtain                                                                                        020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 – Smart Mobility as a Service (SMaaS).  mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to  listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGGUPCMUPQPUM

Close

×

RNS Number : 3908E

Transense Technologies PLC

18 July 2016

 

18 July 2016

 

Transense Technologies Plc

("Transense" or "the Company")

Licence Agreement with GE

 

Transense Technologies Plc (AIM: TRT), the provider of sensor systems for the transportation and industrial markets, is pleased to announce that it has signed a licencing agreement (the "Agreement") with General Electric Company ("GE") for the use of Transense's patented, wireless, passive Surface Acoustic Wave (SAW) technology in certain specific torque applications.

The Agreement, which is non-exclusive, provides for a non-refundable payment to Transense of US$500,000 on signing.  GE will pay a further non-refundable payment to Transense of US$250,000, subject to the Company's SAW technology passing various tests to be conducted by GE.  Should GE not make this further payment by 30 June 2017, the licence will terminate. In addition, GE will pay a perpetual sales royalty to the Company in respect of each unit using the technology.

Graham Storey, CEO of Transense Technologies, said:  "The signing of this licensing agreement with GE is a very significant development for Transense.  Having worked closely with GE since the signing of the memorandum of understanding a year ago, we are very pleased that they have recognised the value of incorporating our SAW technology in certain of their products and are making this commitment.  As the licence to GE is both non-exclusive and is valid for only a relatively narrow field of use it clearly benchmarks the overall value of the Company's IP portfolio. We continue to work with other potential partners to deploy our SAW technology in the commercial environment."

 

For further information please visit www.transense.co.uk or contact:

 

Transense Technologies Plc Graham Storey, Chief Executive	Tel: +44 (0) 1869 238380
finnCap Ed Frisby, Giles Rolls (Corporate Finance) Tony Quirke, Alice Lane (Corporate Broking)	Tel: +44 (0) 20 7220 0500
IFC Advisory Tim Metcalfe, Graham Herring, Heather Armstrong	Tel: +44 (0) 20 3053 8671

 

 

 

 

About GE

GE (NYSE: GE) is the world's Digital Industrial Company, transforming industry with software-defined machines and solutions that are connected, responsive and predictive. GE is organized around a global exchange of knowledge, the "GE Store" through which each business shares and accesses the same technology, markets, structure and intellect. Each invention further fuels innovation and application across our industrial sectors. With people, services, technology and scale, GE delivers better outcomes for customers by speaking the language of industry. www.ge.com.

 

 

About Transense Technologies

Based in Oxfordshire, UK, Transense has developed patent-protected sensor systems and supporting technology for use in a variety of diverse high growth markets. Transense's Surface Acoustic Wave (SAW), wireless, battery-less, sensor systems offer significant advantages over legacy wireless sensor systems. Transense is targeting the transport and mining industries, and the global torque, temperature and pressure sensing markets, via its trading divisions, Translogik and SAWSense.

Transense's shares are admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT).

www.transense.co.uk

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRSFDFAWFMSEDW

Close

×

RNS Number : 1316E

Crimson Tide PLC

14 July 2016

 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected for pharmaceutical verification pilot

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 – Smart Mobility as a Service, has won a contract for the initial stage of a significant healthcare pilot project in Asia for the serialisation and verification of pharmaceutical products. The pilot project is being implemented under the auspices of the Asia Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF), Committee on Trade and Investment (CTI) and Business Advisory Council (ABAC).

 

Selected by a consortium of pharma organisations, the technology platform for the demonstration phase of the pilot project will leverage mpro5 to scan pharmaceutical products, generating an anonymous verification request to the product's manufacturer.   The pilot project seeks to demonstrate for the first time the ability to verify serialised pharmaceutical products from various scan locations to source data stored in distributed databases using global data standards.  The pilot also seeks to promote harmonisation by demonstrating the ability to use a single or reproducible data gateway in multiple countries.

 

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security.  This enables real-time information upload, quick verifications and multi-way data request transmittals.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "The global impact of drug serialisation and verification cannot be underestimated. I am delighted that we have been chosen to help in this pilot project in Asia, as it opens up significant opportunities in the pharma world."

 

‐ ends ‐

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp                                                                                       01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister                                                             020 7220 1666

Allerton Communications

Peter Curtain                                                                                        020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 – Smart Mobility as a Service (SMaaS).  mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to  listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTEAPXDFFLKEFF

Close

×

RNS Number : 9675D

Vela Technologies PLC

12 July 2016

 

12 July 2016

 

Vela Technologies plc

 

("Vela" or the "Company")

 

Proactive interview

The Board of Vela (AIM: VELA), the investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to provide an opportunity to watch a video interview Proactive Investors recently conducted with Antony Laiker. The video interview, along with an accompany written editorial, can be accessed on Proactive Investor's website at the following address:

http://www.proactiveinvestors.co.uk/companies/stocktube/5264/vela-technologies-looking-for-the-game-changers-says-ceo-5264.html.

 

For further information, please contact:

Vela Technologies plc   Brent Fitzpatrick, Non-Executive Chairman Antony Laiker, Director       Tel: +44 (0) 7802 262 443   Allenby Capital Limited (Nominated Adviser)   Nick Athanas/Katrina Perez   Smaller Company Capital Limited (Broker) Rupert Williams/Jeremy Woodgate       Tel: +44 (0) 20 3328 5656       Tel: +44 (0) 20 3651 2910

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAAKBDBBBKDFOD

Close

×

RNS Number : 5179D

Midatech Pharma PLC

07 July 2016

 

 

 

 

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy

 

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, today announces that its research collaboration with Cardiff University in autoimmune therapies has received a two-year funding grant from JDRF (Juvenile Diabetes Research Foundation), for a project entitled "Gold nanoparticles coupled with selective PAMP ligands to deliver antigen specific immunotherapy" in diabetes, the commonest autoimmune disease worldwide.

 

The project, using Midatech's platform gold nanoparticle technology, will focus on developing tolerogenic mechanisms that dampen unwanted autoimmune responses to normal healthy cells in the pancreas, thus preserving the ability of these cells to continue producing insulin.  It will be led by Professor Colin Dayan, Professor of Clinical Diabetes and Metabolism, Cardiff University, and is due to start in October 2016. The total value of the grant is $477,437, of which $150,000 is due to Midatech.

 

Commenting on the grant, Dr Jim Phillips, CEO of Midatech said: "The application of gold nanoparticle technology in immunotherapy is developing rapidly and presents a significant opportunity to make a difference in the treatment of autoimmune diseases such diabetes, as well as our increasing focus on oncology indications including of brain, liver, pancreatic and ovarian cancer. The interest in applying Midatech's proprietary technology across a broad range of therapies demonstrates the potential of the platform and for the Group's pipeline."

 

Professor Colin Dayan, leading the project at Cardiff University, added: "Cardiff University looks forward to this continued collaboration using Midatech's gold nanoparticle (GNP) technology which has shown great potential to preferentially target specific immune cells, distribute rapidly to lymphoid tissues around the body, and modify the body's immune responses.  This will be an important project for autoimmune diseases generally and diabetes specifically, and we are looking forward to developing this platform combination of Midatech GNP technology, and antigen-specific immunotherapy using a wide variety of tolerogenic small partner molecules."

 

– ENDS –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie / Duncan Monteith

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

RBC Europe Limited (Joint Broker)

Paul Tomasic / Rupert Walford / Thomas Stockman / Laura White

Tel: +44 (0)207 653 4000

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for diabetes or other conditions using the nanoparticle drug delivery platform, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRARRMRTMBBMMIF

Close

×

RNS Number : 3425D

Obtala Resources Limited

06 July 2016

 

06 July 2016

Obtala Resources Limited

("Obtala", the "Group" or the "Company")

(AIM: OBT)

 

 

Forestry Update

 

Obtala Resources Limited (AIM:OBT), the African focused agricultural and forestry company, announces today that it has received full payment of US$500,000 from two investors, one of whom being The Chairman, as per the investment agreement announced on the 30 June 2016.

The investment proceeds will be used to further develop production capabilities within the Forestry division by building additional drying units and investing in other operating machinery.

 

 

Obtala Resources Miles Pelham – Chairman Paul Dolan – CEO www.obtalaresources.com	+44 (0)20 7099 194
ZAI Corporate Finance Limited (Nomad)                 Ray Zimmerman/Peter Trevelyan-Clark/Jamie Spotswood	+44 (0)20 7060 2220
Brandon Hill Capital  (Broker)      Jonathan Evans	+44 (0)20 3463 5000

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

STRBELLBQDFZBBK

Close